InvestorsHub Logo
Followers 135
Posts 8871
Boards Moderated 1
Alias Born 12/31/2004

Re: None

Tuesday, 04/10/2018 9:00:13 PM

Tuesday, April 10, 2018 9:00:13 PM

Post# of 65774
Why I believe Q2 revenues will leap frog going forward. With a Nov. 17 pesticide license and recent acquisition of C3 Labs I believe we will be up minimum 20% revenues from Q1. Take note that C3 did $1 Mil over the prior 2 years which comes to 125K per Q. That is annualized and with the new rules could be higher. Take note that with 60% ownership they will be able to count all revenues as majority owned. IMO, $1.2Mil+ for Q ending.

“The addition of C3 Labs to the EVIO network is a tremendous milestone for EVIO Inc. C3 Labs generated over US$1 million in consulting revenues during the last two years, EVIO plans to continue offering these services along with traditional compliance testing. The 8,000 ft2 is already outfitted with the latest analytical testing equipment and will become our Northern California hub laboratory,” said William Waldrop EVIO CEO.

Also this was consulting revenues only with very high margins. It appears from this link we have no clue to the amount of testing capabilities or competition. Surely somebody can enlighten us here as I really am clueless as to expectations here for Q2.


https://www.cleanroomtechnology.com/news/article_page/EVIO_acquires_licenced_California_cannabis_testing_laboratory/138156